Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.

Stanford scientists are using CRISPR to model individual patients’ hearts and identify which gene variants raise their risk of sudden cardiac death.

Researchers from King's College London designed a gene therapy that can be switched off once it has treated a spinal cord injury.

French biotech Cellectis has devised a form of CAR-T that contains its therapeutic effects with a safeguard in a single molecule.

Scientists at American University have discovered a potential method for treating obesity.

Biotech developments over the past week include using circulating RNA to predict preemie births and a new way to free up stiffened heart muscle.

The discovery of inherited genetic variants that raise the risk of prostate cancer could improve screening, treatment and prevention of the disease.

Transplanting pancreatic islets, along with a hydrogel that "trains" immune cells to accept them, could translate to a cure for Type 1 diabetes.

The genetic map could highlight potential therapeutic targets, help repurpose drugs for new indications and identify side effects.

Two new studies suggest that blocking the cytokine IL-1 with a rheumatoid arthritis drug could treat neurological side effects of CAR-T treatments.